Forte Biosciences (FBRX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Dermatologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 48/100 (MEDIUM), 58.0 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: ?% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Argenx (ENXTBR:ARGX) Completes Forte Biosciences Acquisition
- argenx (ENXTBR:ARGX) Is Considering A Forte Biosciences Acquisition
- The Charts Reveal Significant Price Movement in Forte Biosciences Stock Ahead of Argenx’s Acquisition Announcement
- Forte Biosciences (FBRX) Agrees To argenx Takeover As Tender Offer Nears
- argenx (ENXTBR:ARGX) Could Be 15% Above Fair Value On The Forte Deal
- Dallas biopharmaceutical company sells for more than $2 billion
- The $2.2 Billion Reason Forte BioSciences (FBRX) Stock Is Skyrocketing Today
- Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Identification, Structure-Activity Relationship (SAR), and Biological Evaluation of New Chemical Series as Malaria Parasite PfGCN5 Bromodomain Inhibitors. — ACS Omega 2026 Sep 15 PMID 42757160
- Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study. — Lancet 2026 Aug 29 PMID 42628554
- Comparative outcomes of Forte versus Delta ceramic bearings in total hip arthroplasty using a national database. — Sci Rep 2026 Aug 20 PMID 42618575
- Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies. — Lancet 2026 Aug 15 PMID 42594914
- Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials. — Am J Clin Dermatol 2026 Sep PMID 42563042
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Forte Biosciences.
Full FBRX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.